Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 4/2015

01-04-2015 | Editorial

Direct to Consumer Advertising: The Case for Greater Consumer Control

Authors: Idris Guessous, MD, PhD, Chiranjeev Dash, MBBS, MPH, PhD

Published in: Journal of General Internal Medicine | Issue 4/2015

Login to get access

Excerpt

Anyone traveling to the United States from countries other than New Zealand will be surprised by the prevalence of health-related advertisements on television, including ads for drugs. Typically, these TV ads follow a pattern: an ad for a burger at only 99 cents, followed by one for a proton-pump inhibitor, then an ad on healthy home-cooked food delivered directly to your home and an ad for a home-based abdominal workout DVD, followed by an ad for a lipid-lowering drug. There are, however, nuances. After 8 pm, the visitor might encounter an ad for the “little blue pill.” This sequence sometimes includes an ad featuring antihistamines for allergic rhinitis in spring and one promoting antidepressants in the winter. …
Literature
1.
Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA. 1999;281(4):380–2.CrossRefPubMed
2.
Mintzes B. Advertising of prescription-only medicines to the public: does evidence of benefit counterbalance harm? Annu Rev Public Health. 2012;33:259–77.CrossRefPubMed
3.
4.
5.
Shuchman M. Drug risks and free speech—can Congress ban consumer drug ads? N Engl J Med. 2007;356(22):2236–9.CrossRefPubMed
6.
Fain KM, Alexander GC. Mind the gap: understanding the effects of pharmaceutical direct-to-consumer advertising. Med Care. 2014;52(4):291–3.PubMed
7.
Skeldon SC, Kozhimannil KB, Majumdar SR, Law MR. The effect of competing direct-to-consumer advertising campaigns on the use of drugs for benign prostatic hyperplasia: time series analysis. J Gen Intern Med. 2014. doi:10.​1007/​s11606-014-3063-y.PubMed
8.
Collins MM, Barry MJ, Bin L, Roberts RG, Oesterling JE, Fowler FJ. Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physicians. J Gen Intern Med. 1997;12(4):224–9.PubMedCentralPubMed
9.
Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995–2002.CrossRefPubMedCentralPubMed
10.
AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 2003;170(2 Pt 1):530–47.
11.
Kravitz RL, Bell RA. Direct-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward. Clin Pharmacol Ther. 2007;82(4):360–2.CrossRefPubMed
12.
Kravitz RL, Bell RA. Media, messages, and medication: strategies to reconcile what patients hear, what they want, and what they need from medications. BMC Med Informa Decis Making. 2013;13(Suppl 3):S5.CrossRef
13.
Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med. 2007;357(7):673–81.CrossRefPubMed
14.
Bell RA, Wilkes MS, Kravitz RL. The educational value of consumer-targeted prescription drug print advertising. J Fam Pract. 2000;49(12):1092–8.PubMed
Metadata
Title
Direct to Consumer Advertising: The Case for Greater Consumer Control
Authors
Idris Guessous, MD, PhD
Chiranjeev Dash, MBBS, MPH, PhD
Publication date
01-04-2015
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 4/2015
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-015-3187-8

Other articles of this Issue 4/2015

Journal of General Internal Medicine 4/2015 Go to the issue

Editorial

TRANSFORM-ing Patient Safety Culture: A Universal Imperative

Letter to the Editor

Perineal Self-Acupressure’s Mechanism of Action

Capsule Commentary

Capsule Commentary on Ratelle et al., Predicting and Communicating Risk of Clinical Deterioration: An Observational Cohort Study of Internal Medicine Residents

Original Research

The TRANSFORM Patient Safety Project: A Microsystem Approach to Improving Outcomes on Inpatient Units

Capsule Commentary

Capsule Commentary on Abbot et al., Effect of Perineal Self-Acupressure on Constipation: A Randomized Controlled Trial

Perspective

The Need for Higher Standards in Correctional Healthcare to Improve Public Health
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits